Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

4 support catheters receive FDA clearance for coronary use

The catheters were developed to be used during percutaneous coronary intervention procedures for coronary artery disease. 

TricValve Transcatheter Bicaval Valves System Cleveland Clinic

Interventional cardiologists complete first heart procedure of its kind in North America

While the system used during the procedure has not yet gained full FDA approval, this patient was treated under a compassionate-use clearance from the agency.

A view showing the close relationship between the mitral and aortic valves and how the overhang of a longer TAVR valve can interfere with the left ventricular outflow tract (LVOT). Image from a mitral echo assessment using Siemens eSie Valves software at ACC22.

The latest data on mitral valve infective endocarditis after TAVR

Self-expanding heart valves and the presence of significant PVL were both linked to a heightened risk of mitral valve infective endocarditis after TAVR. 

virtual reality endovascular surgery

Virtual reality specialists launch new training solutions for endovascular surgery

The virtual reality training sessions were designed to feature "the same sights, sound and sensations a surgeon would encounter during real procedures." 

Drug-coated balloons comparable to drug-eluting stents when PCI patients have a high bleeding risk

Drug-coated balloons were associated with a lower risk of bleeding after PCI than drug-eluting stents, the study's authors reported. 

VIDEO: TAVR durability outperforms surgical valves

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Adam Greenbaum, MD, Emory, explains the CLASP TR trial of the Pascal clip device for transcatheter repair, which was a late-breaking ACC22 study.

VIDEO: Pascal effective in transcatheter repair of tricuspid valve regurgitation

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several ACC 2022 late-breaking trials may have impacts on clinical practice for interventional cardiology and structural heart. One trial compared FFR vs. IVUS guided PCI for intermediate coronary lesions. Photos by Dave Fornell

Key interventional cardiology takeaways from ACC.22

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.